Literature DB >> 23849147

Bayesian adaptive trials offer advantages in comparative effectiveness trials: an example in status epilepticus.

Jason T Connor1, Jordan J Elm, Kristine R Broglio.   

Abstract

OBJECTIVE: We present a novel Bayesian adaptive comparative effectiveness trial comparing three treatments for status epilepticus that uses adaptive randomization with potential early stopping. STUDY DESIGN AND
SETTING: The trial will enroll 720 unique patients in emergency departments and uses a Bayesian adaptive design.
RESULTS: The trial design is compared to a trial without adaptive randomization and produces an efficient trial in which a higher proportion of patients are likely to be randomized to the most effective treatment arm while generally using fewer total patients and offers higher power than an analogous trial with fixed randomization when identifying a superior treatment.
CONCLUSION: When one treatment is superior to the other two, the trial design provides better patient care, higher power, and a lower expected sample size.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adaptive sample size; Bayesian adaptive trials; Comparative effectiveness research; Emergency medicine; Response adaptive randomization; Status epilepticus

Mesh:

Substances:

Year:  2013        PMID: 23849147      PMCID: PMC3743558          DOI: 10.1016/j.jclinepi.2013.02.015

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  12 in total

Review 1.  The methods of comparative effectiveness research.

Authors:  Harold C Sox; Steven N Goodman
Journal:  Annu Rev Public Health       Date:  2012-01-03       Impact factor: 21.981

2.  Adaptive clinical trials: a partial remedy for the therapeutic misconception?

Authors:  William J Meurer; Roger J Lewis; Donald A Berry
Journal:  JAMA       Date:  2012-06-13       Impact factor: 56.272

3.  Barriers and opportunities for implementation of adaptive designs in pharmaceutical product development.

Authors:  Judith Quinlan; Brenda Gaydos; Jeff Maca; Michael Krams
Journal:  Clin Trials       Date:  2010-03-25       Impact factor: 2.486

4.  Adaptive clinical trials: the promise and the caution.

Authors:  Donald A Berry
Journal:  J Clin Oncol       Date:  2010-12-20       Impact factor: 44.544

5.  Rethinking randomized clinical trials for comparative effectiveness research: the need for transformational change.

Authors:  Bryan R Luce; Judith M Kramer; Steven N Goodman; Jason T Connor; Sean Tunis; Danielle Whicher; J Sanford Schwartz
Journal:  Ann Intern Med       Date:  2009-06-30       Impact factor: 25.391

6.  An overview of the adaptive designs accelerating promising trials into treatments (ADAPT-IT) project.

Authors:  William J Meurer; Roger J Lewis; Danilo Tagle; Michael D Fetters; Laurie Legocki; Scott Berry; Jason Connor; Valerie Durkalski; Jordan Elm; Wenle Zhao; Shirley Frederiksen; Robert Silbergleit; Yuko Palesch; Donald A Berry; William G Barsan
Journal:  Ann Emerg Med       Date:  2012-03-15       Impact factor: 5.721

7.  Step-forward randomization in multicenter emergency treatment clinical trials.

Authors:  Wenle Zhao; Jody Ciolino; Yuko Palesch
Journal:  Acad Emerg Med       Date:  2010-06       Impact factor: 3.451

8.  Pharmacokinetics of intravenous lorazepam in pediatric patients with and without status epilepticus.

Authors:  James M Chamberlain; Edmund V Capparelli; Kathleen M Brown; Cheryl W Vance; Kathleen Lillis; Prashant Mahajan; Richard Lichenstein; Rachel M Stanley; Colleen O Davis; Stephen Gordon; Jill M Baren; John N van den Anker
Journal:  J Pediatr       Date:  2011-11-01       Impact factor: 4.406

9.  Intramuscular versus intravenous therapy for prehospital status epilepticus.

Authors:  Robert Silbergleit; Valerie Durkalski; Daniel Lowenstein; Robin Conwit; Arthur Pancioli; Yuko Palesch; William Barsan
Journal:  N Engl J Med       Date:  2012-02-16       Impact factor: 91.245

10.  The Albumin in Acute Stroke Part 1 Trial: an exploratory efficacy analysis.

Authors:  Michael D Hill; Renee H Martin; Yuko Y Palesch; Diego Tamariz; Bonnie D Waldman; Karla J Ryckborst; Claudia S Moy; William G Barsan; Myron D Ginsberg
Journal:  Stroke       Date:  2011-05-05       Impact factor: 7.914

View more
  29 in total

1.  Optimal delay time to initiate anticoagulation after ischemic stroke in atrial fibrillation (START): Methodology of a pragmatic, response-adaptive, prospective randomized clinical trial.

Authors:  Benjamin T King; Patrick D Lawrence; Truman J Milling; Steven J Warach
Journal:  Int J Stroke       Date:  2019-08-18       Impact factor: 5.266

2.  Building efficient comparative effectiveness trials through adaptive designs, utility functions, and accrual rate optimization: finding the sweet spot.

Authors:  Byron J Gajewski; Scott M Berry; Melanie Quintana; Mamatha Pasnoor; Mazen Dimachkie; Laura Herbelin; Richard Barohn
Journal:  Stat Med       Date:  2015-01-07       Impact factor: 2.373

3.  Answering patient-centred questions efficiently: response-adaptive platform trials in primary care.

Authors:  Christopher C Butler; Jason T Connor; Roger J Lewis; Kristine Broglio; Benjamin R Saville; Johanna Cook; Alike van der Velden; Theo Verheij
Journal:  Br J Gen Pract       Date:  2018-06       Impact factor: 5.386

4.  Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus.

Authors:  Jaideep Kapur; Jordan Elm; James M Chamberlain; William Barsan; James Cloyd; Daniel Lowenstein; Shlomo Shinnar; Robin Conwit; Caitlyn Meinzer; Hannah Cock; Nathan Fountain; Jason T Connor; Robert Silbergleit
Journal:  N Engl J Med       Date:  2019-11-28       Impact factor: 91.245

5.  Does accounting for seizure frequency variability increase clinical trial power?

Authors:  Daniel M Goldenholz; Shira R Goldenholz; Robert Moss; Jacqueline French; Daniel Lowenstein; Ruben Kuzniecky; Sheryl Haut; Sabrina Cristofaro; Kamil Detyniecki; John Hixson; Philippa Karoly; Mark Cook; Alex Strashny; William H Theodore; Carl Pieper
Journal:  Epilepsy Res       Date:  2017-07-25       Impact factor: 3.045

6.  A conceptual model for the development process of confirmatory adaptive clinical trials within an emergency research network.

Authors:  Samkeliso C Mawocha; Michael D Fetters; Laurie J Legocki; Timothy C Guetterman; Shirley Frederiksen; William G Barsan; Roger J Lewis; Donald A Berry; William J Meurer
Journal:  Clin Trials       Date:  2017-01-31       Impact factor: 2.486

7.  The established status epilepticus trial 2013.

Authors:  Thomas Bleck; Hannah Cock; James Chamberlain; James Cloyd; Jason Connor; Jordan Elm; Nathan Fountain; Elizabeth Jones; Daniel Lowenstein; Shlomo Shinnar; Robert Silbergleit; David Treiman; Eugen Trinka; Jaideep Kapur
Journal:  Epilepsia       Date:  2013-09       Impact factor: 5.864

8.  Adaptive designs for comparative effectiveness research trials.

Authors:  John A Kairalla; Christopher S Coffey; Mitchell A Thomann; Ronald I Shorr; Keith E Muller
Journal:  Clin Res Regul Aff       Date:  2014-11-13

9.  Mass weighted urn design--A new randomization algorithm for unequal allocations.

Authors:  Wenle Zhao
Journal:  Contemp Clin Trials       Date:  2015-06-17       Impact factor: 2.226

10.  The utility of Bayesian predictive probabilities for interim monitoring of clinical trials.

Authors:  Benjamin R Saville; Jason T Connor; Gregory D Ayers; JoAnn Alvarez
Journal:  Clin Trials       Date:  2014-05-28       Impact factor: 2.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.